Starling Oncology, Inc. Proceeds from Long-Term Debt Issued
Starling Oncology, Inc. (STLN) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-03-28
- Starling Oncology, Inc. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was $0.00.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for fiscal 2022 was $110.00M.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Starling Oncology, Inc. proceeds from issuance of long-term debt for fiscal 2020 was $12.49M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $110.00M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $110.00M 10-Q · filed 2023-11-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $12.49M 10-K · filed 2022-03-11 |